title: [Cancer screening: unsupported promises from Pathway Genomics].
abstract: The "liquid biopsy" approach shows promise for characterization and monitoring of cancer during treatment; however a blood-based detection test for "high-risk" but asymptomatic individuals, recently introduced by Pathway Genomics, lacks supporting data and has no proven clinical utility.
authors.affiliation: UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hospital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France - CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Jordan
mesh_terms: D055088:Early Detection of Cancer; D023281:Genomics; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000235:genetics